Estimated read time: 5-6 minutes
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
[STK]
[IN] HEA MTC BIO
[SU] AWD TDS
-- WITH PHOTO -- TO BUSINESS, AND HEALTH EDITORS:
Kibow Biotech of Newtown Square, Pennsylvania -- First Dietary
Supplement Company, Nominated to Participate in the "Buzz of BIO"-
Pipelines of Promise Category at the 2014 BIO International
Convention.
NEWTOWN SQUARE, Pa., April 15, 2014 /PRNewswire/ -- Kibow Biotech is
pleased to participate in the Buzz of BIO for the 2014 BIO
International Convention. Hosted by the Biotechnology Industry
Organization (BIO), this year's global event for biotechnology will
take place June 23-26, 2014 at the San Diego Convention Center in
California. During the Buzz of BIO contest, industry leaders as well
as the general public will be voting for companies they want to see at
the event's BIO Business Forum. Voting will take place online from
April 15 through April 22 at
http://convention.bio.org/buzzofbio/voting.aspx.
Logo - http://photos.prnewswire.com/prnh/20140414/73029 Logo -
http://photos.prnewswire.com/prnh/20140414/73030
This is the first time that a biotechnology business company
exclusively specializing on dietary supplement products is being
recognized as one of the selected and nominated among 40 U.S.
companies for the "Pipeline of Promise or Technologies of Tomorrow"
category. Dr. Natarajan Ranganathan - the co-founder and chief R&D
scientist says that "the decade of research efforts on the concept of
balancing the gut microbiome with probiotics (beneficial health
impacting microbes) is finally gaining more recognition". He also
added that a scientific basis and rationale for "a shift from human
genome to gut microbiome" has been established only recently, and the
process of using it to address various healthcare problems is just
beginning.
Kibow's management believes that despite being a dietary supplement
company, Kibow was selected because of the scientific and drug-like
validation of its patented, proprietary probiotic product for
maintaining healthy kidney function. Kibow is best known for its
veterinary (Azodyl@) and human (RenadylT) products for individuals
with kidney failure problems.
The company's nomination is a cumulative impact of its earlier
selection for a poster presentation as Emerging Biotech Company at the
BIO-Boston meeting, its novel concept, and its pharmaceutical-like
validation of the product based on "enteric uremic toxin reduction
technology" (Enteric Dialysis@). This dietary supplement product, in
combination with the standard-of-care treatment for primary diseases
such as diabetes, hypertension and other related conditions, may help
delay the progression to dialysis status. Subject to additional
clinical trials and its validation, the product also possesses an
excellent potential to reduce the frequency or duration of dialysis,
affording better outcomes and saving billions of healthcare dollars
worldwide. Kibow and its R&D team have also developed a proprietary
blend of prebiotics for multitargeted wellness application and is
looking for partnering with a major INTERNATIONAL pharmaceutical or
Biotech Company. (continued)
ABOUT THE BIO INTERNATIONAL CONVENTION
The largest, most influential biotech meeting in the world is coming
to the San Diego Convention Center, June 23-26, 2014, offering four
days of career-boosting opportunities that you won't find anywhere
else-from sessions and specialty forums covering 17 hot topics to
networking events, 1,700+ exhibitors and BIO One-on-One
Partnering meetings with thousands of companies. Join the global
biotech community in San Diego and discover where BIO 2014 can take
you. Register now at convention.bio.org.
ABOUT KIBOW BIOTECH INC:
About Kibow Biotech: Founded in Oct 1, 1997 in Philadelphia, Kibow
Biotech specializes in research, development and commercialization of
probiotic dietary supplements adhering to US FDA and FTC regulations.
The Company's primary mission is to offer affordable, readily
available and easily administered dietary supplements in support of
kidney health and other healthcare applications. The Company's
flagship product, RenadylT, is currently marketed in the U.S. and
Canada, and will progressively be made available worldwide, according
to individual countries' governmental rules and regulatory
authorities.
About Enteric Uremic Toxin Reduction Technology:
Kibow's novel "enteric uremic toxin reduction technology" addresses
the accumulation of various uremic toxins which diffuse into the bowel
as a consequence of failing kidney function. The Company's patented
and proprietary dietary supplements, RenadylT (for humans) and Azodyl@
(veterinary formulation) consist of a combination of three specific
probiotic microbial strains. The results of various clinical trials,
including the latest conducted in 2012, have provided encouraging
preliminary evidence that the Company's technology could be effective
when the product formulation is taken regularly according to medical
directives and in a context of standard care as dictated by individual
conditions.
Forward-looking statements: This press release contains
forward-looking statements that reflect management's current views of
future events, including the current status of development of the
dietary supplement formulation, RenadylT, for kidney health in the USA
and the possibility of its approval as a drug or food supplement in
some other countries according to respective governmental authorities.
Kibow is not a pharmaceutical company. Kibow products are not drugs
and may not be considered as a treatment or a prevention product or
therapy. The dietary supplement formulation of RenadylT will not cure,
prevent or mitigate any disease. Other factors that could cause or
contribute to differences in actual results include, but are not
limited to, risks associated with any future clinical trials of
product candidates, the possibility that testing may reveal to be
undesirable and unintended side effects or other characteristics that
may prevent or limit the commercial use of proposed products; whether
the cash resources of the Company will be sufficient to fund
operations as planned; reliance on key employees, especially senior
management; the uncertainty of the Company's future access to capital;
the risk that the Company may not secure or maintain relationships
with collaborators; and the Company's dependence on intellectual
property. The Company expressly disclaims any intent or obligation to
update these forward-looking statements except as required by law.
Contact:
Mary Galambert KIBOW BIOTECH INC 610-353-5130 ext. 225
WWW.KIBOWBIOTECH.COM
Read more news from Kibow Biotech Inc.
SOURCE Kibow Biotech
-0- 04/15/2014
/Photo: http://photos.prnewswire.com/prnh/20140414/73029
http://photos.prnewswire.com/prnh/20140414/73030
PRN Photo Desk, photodesk@prnewswire.com
/Web Site: http://www.kibowbiotech.com
CO: Kibow Biotech
ST: Pennsylvania
IN: HEA MTC BIO
SU: AWD TDS
PRN
-- PH04846 --
0000 04/15/2014 12:30:00 EDT http://www.prnewswire.com
Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
